Assays targeting the promoter CpG islands of the CDKN2A and RARB genes were designed to evaluate the quality of the samples since aberrant methylation of these genes is implicated in NSCLC [29], and especially CDKN2A has shown promising results as a biomarker for early detection [30]. This evidence concerns the gene RARB and non-small cell lung carcinoma.